Drug
Relugolix clinical trials
Also written TAK-385, Orgovyx and MVT-601.
- studies test it
- 42
- open now
- 13
- in phase 3
- 17
- first study started
- 2011
Keep track of what changes. Save the relugolix studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
- Orgovyx
- 13
Studies by the year they started
42 studies that test it; most in 2024 (11)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 6 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 11 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 8
- Phase 2
- 16
- Phase 3
- 17
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 17
Myovant Sciences GmbH (9) · Takeda (9) · Millennium Pharmaceuticals, Inc. (3) · NRG Oncology (2) · Emory University (2) · Atish Choudhury, MD (1) · Sumitomo Pharma America, Inc. (1) · Urology Clinics of North Texas (1)
Often tested with
Tested in the same studies.
Estradiol (8) · Norethindrone Acetate (8) · Norethindrone (8) · Leuprolide (5) · Darolutamide (3) · Bicalutamide (2) · Degarelix (2) · Triptorelin (2)
Studies
Open first, then newest update. How each study uses relugolix is read from its arms, and is right about nine times in ten.
Testing it · 42
- Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA TrialRecruitingPhase 2Mayo ClinicNCT07025369Written as Relugolix
- The SUGAR Study; SBRT and Relugolix) for Prostate CancerRecruitingPhase 2Yale UniversityNCT06111781Written as Relugolix 120 MG [Orgovyx]
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CTRecruitingPhase 2Baptist Health South FloridaNCT07455903Written as Relugolix
- RecoverPC: Relugolix vs GnRH Agonist in Quality of LifeRecruitingPhase 2Dana-Farber Cancer InstituteNCT05765500Written as Relugolix
- The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled TrialRecruitingPhase 3Main Line HealthNCT06439524Written as 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate
- Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL TrialRecruitingPhase 2Sean SachdevNCT06499870Written as Relugolix
- Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate CancerRecruitingPhase 2Ohio State University Comprehensive Cancer CenterNCT06330805Written as Relugolix
- Relugolix + Enzalutamide Study in High-Risk Prostate CancerRecruitingPhase 1University of OklahomaNCT06130995Written as Relugolix and Enzalutamide
- REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac TrialRecruitingPhase 3Emory UniversityNCT06650579Written as Relugolix
- Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate CancerRecruitingPhase 1AdventHealthNCT06631521Written as Relugolix
- Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine FibroidsRecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT06671548Written as Relugolix
- A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or EndometriosisRecruitingPhase 3Sumitomo Pharma Switzerland GmbHNCT05862272Written as Relugolix Combination Tablet
- Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate CancerNot yet recruitingPhase 2University of Kansas Medical CenterNCT06129851Written as Relugolix
- Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean StudyActive, not recruitingPhase 2NRG OncologyNCT05053152Written as Relugolix
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialActive, not recruitingPhase 3NRG OncologyNCT05050084Written as Relugolix
- Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide AcetateCompletedPhase 3Sumitomo Pharma America, Inc.NCT05605964Written as Relugolix
- Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)Active, not recruitingPhase 2Atish Choudhury, MDNCT06463457Written as Relugolix
- RElugolix VErsus LeUprolide Cardiac TrialActive, not recruitingPhase 2Emory UniversityNCT05320406Written as Relugolix
- Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy TreatmentWithdrawnPhase 2Endeavor HealthNCT06279195Written as Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet
- Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy StagingCompletedEarly Phase 1Urology Clinics of North TexasNCT07069465Written as Relugolix 120 MG
See all 42 studies that test relugolix →
Given in every arm · 6 — relugolix is usual care beside what is tested
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET ImagingRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT04423211Written as Relugolix
- Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate CancerActive, not recruitingPhase 2/3VA Office of Research and DevelopmentNCT04787744Written as Degarelix & Relugolix
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialActive, not recruitingPhase 3NRG OncologyNCT04513717Written as Relugolix
- A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for MetastasesCompletedPhase 2Janssen Research & Development, LLCNCT04523207Written as Relugolix
- Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate CancerCompletedPhase 1Sumitomo Pharma America, Inc.NCT04666129Written as Relugolix
- Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female ParticipantsCompletedPhase 1Myovant Sciences GmbHNCT04978688Written as Relugolix
As the comparator · 2 — what is tested is compared with relugolix
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialRecruitingPhase 2Mayo ClinicNCT06378866Written as Relugolix
- Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17Not yet recruitingPhase 1/2University of WashingtonNCT06312761Written as Relugolix 120Mg Tab
Codes
What other systems call relugolix · ClinicalTrials.gg INT005900
- MeSH (NLM) C561634relugolixOne source ClinicalTrials.gov
- UNII (FDA) P76B05O5V6RELUGOLIXConfirmed FDA, Wikidata
- RxNorm 2472778One source FDA
- Wikidata Q21099000relugolixConfirmed FDA, Wikidata
- NCI Thesaurus C114498RelugolixOne source FDA
- DrugBank DB11853One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C561634 | relugolix | One source ClinicalTrials.gov |
| UNII (FDA) | P76B05O5V6 | RELUGOLIX | Confirmed FDA, Wikidata |
| RxNorm | 2472778 | — | One source FDA |
| Wikidata | Q21099000 | relugolix | Confirmed FDA, Wikidata |
| NCI Thesaurus | C114498 | Relugolix | One source FDA |
| DrugBank | DB11853 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.